Vulnerable plaque and scientific method; industry payments to trainees; tirzepatide or semaglutide; trial interpretation; and PFA are the topics John Mandrola, MD, covers in today’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Non-invasive Imaging for Vulnerable Plaque
PET Imaging Finds Vulnerable Plaques That Cause MI
https://www.medscape.com/viewarticle/pet-imaging-finds-vulnerable-plaques-cause-mi-2024a1000cm2
II. Industry Payments to Fellows
III. GLP-1a Class Effect?
Semaglutide Significantly Improves Chronic Kidney Disease
https://www.medscape.com/viewarticle/semaglutide-significantly-improves-chronic-kidney-disease-2024a10009w9
Mounjaro Beats Ozempic, So Why Isn’t It More Popular?
https://www.medscape.com/viewarticle/mounjaro-beats-ozempic-so-why-isnt-it-more-popular-2024a1000ckd
IV. Colchicine and Trial Interpretation in the Lancet
V. PFA
Pulsed Field Ablation for AF: Are US Electrophysiologists Too Easily Impressed?
https://www.medscape.com/viewarticle/pulsed-field-ablation-af-are-us-electrophysiologists-too-2024a1000d2v
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]